Susquehanna International Group
SAGE

Susquehanna International Group’s Sage Therapeutics SAGE Stock Holding History

Susquehanna International Group’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-95,400
Closed -$870K – 13693
2025
Q2 		$870K Sell
95,400
-135,700
-59% -$998K ﹤0.01% 7790
2025
Q1 		$1.84M Buy
231,100
+172,200
+292% +$1.26M ﹤0.01% 5716
2024
Q4 		$320K Sell
58,900
-46,900
-44% -$287K ﹤0.01% 9701
2024
Q3 		$764K Buy
105,800
+50,500
+91% +$462K ﹤0.01% 7446
2024
Q2 		$601K Buy
55,300
+5,200
+10% +$66.6K ﹤0.01% 7825
2024
Q1 		$939K Buy
50,100
+3,900
+8% +$90K ﹤0.01% 7071
2023
Q4 		$1M Sell
46,200
-87,400
-65% -$1.73M ﹤0.01% 6991
2023
Q3 		$2.75M Buy
133,600
+58,000
+77% +$1.68M ﹤0.01% 4537
2023
Q2 		$3.55M Sell
75,600
-34,800
-32% -$1.73M ﹤0.01% 4081
2023
Q1 		$4.63M Buy
110,400
+102,000
+1,214% +$4.39M ﹤0.01% 3569
2022
Q4 		$320K Sell
8,400
-19,200
-70% -$733K ﹤0.01% 8927
2022
Q3 		$1.08M Sell
27,600
-36,000
-57% -$1.39M ﹤0.01% 6441
2022
Q2 		$2.05M Sell
63,600
-160,500
-72% -$5.38M ﹤0.01% 4869
2022
Q1 		$7.42M Sell
224,100
-7,600
-3% -$286K ﹤0.01% 2978
2021
Q4 		$9.86M Buy
231,700
+5,500
+2% +$230K ﹤0.01% 2736
2021
Q3 		$10M Sell
226,200
-68,800
-23% -$3.16M ﹤0.01% 2867
2021
Q2 		$16.8M Buy
295,000
+109,100
+59% +$7.71M ﹤0.01% 2261
2021
Q1 		$13.9M Sell
185,900
-15,200
-8% -$1.25M ﹤0.01% 2325
2020
Q4 		$17.4M Buy
201,100
+53,900
+37% +$3.97M ﹤0.01% 1893
2020
Q3 		$9M Sell
147,200
-15,100
-9% -$765K ﹤0.01% 2308
2020
Q2 		$6.75M Sell
162,300
-37,300
-19% -$1.35M ﹤0.01% 2614
2020
Q1 		$5.73M Sell
199,600
-209,600
-51% -$12.1M ﹤0.01% 2406
2019
Q4 		$29.5M Buy
409,200
+182,900
+81% +$22.5M 0.01% 1132
2019
Q3 		$31.7M Sell
226,300
-48,800
-18% -$8.16M 0.01% 1002
2019
Q2 		$50.4M Buy
275,100
+46,900
+21% +$8M 0.02% 684
2019
Q1 		$36.3M Sell
228,200
-16,800
-7% -$2.43M 0.01% 802
2018
Q4 		$23.5M Buy
245,000
+91,000
+59% +$10.4M 0.01% 975
2018
Q3 		$21.8M Sell
154,000
-43,300
-22% -$6.68M 0.01% 1258
2018
Q2 		$30.9M Buy
197,300
+22,100
+13% +$3.47M 0.01% 968
2018
Q1 		$28.2M Sell
175,200
-155,500
-47% -$26.4M 0.01% 983
2017
Q4 		$54.5M Sell
330,700
-59,400
-15% -$5.76M 0.02% 651
2017
Q3 		$24.3M Buy
390,100
+138,200
+55% +$10.9M 0.01% 1083
2017
Q2 		$20.1M Sell
251,900
-303,000
-55% -$21.9M 0.01% 1172
2017
Q1 		$39.4M Buy
554,900
+451,400
+436% +$26.4M 0.02% 673
2016
Q4 		$5.29M Sell
103,500
-141,500
-58% -$6.67M ﹤0.01% 2337
2016
Q3 		$11.3M Buy
245,000
+120,900
+97% +$4.92M 0.01% 1430
2016
Q2 		$3.74M Buy
124,100
+108,600
+701% +$3.62M ﹤0.01% 2613
2016
Q1 		$497K Sell
15,500
-3,700
-19% -$130K ﹤0.01% 6409
2015
Q4 		$1.12M Sell
19,200
-37,400
-66% -$1.85M ﹤0.01% 5189
2015
Q3 		$2.4M Sell
56,600
-32,800
-37% -$2.02M ﹤0.01% 3918
2015
Q2 		$6.53M Buy
+89,400
New +$5.75M ﹤0.01% 2532

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Susquehanna International Group's SAGE Position: Q3 2025 in Review

Susquehanna International Group sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 139,666 shares — an estimated $1.27M sold.

Susquehanna International Group first reported a position in SAGE in Q2 2015 and held it in 35 quarters. The position peaked at $43.6M in Q4 2017. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Susquehanna International Group reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Susquehanna International Group sold 139,666 Sage Therapeutics shares in Q3 2025, an estimated $1.27M.
  • Susquehanna International Group first reported a position in Sage Therapeutics in Q2 2015 and held it in 35 quarters.
  • Susquehanna International Group's Sage Therapeutics position peaked at $43.6M in Q4 2017.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.